Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
24/09/2026 23:05
BRIEF-Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency Sept 25 (Reuters) - Prime Medicine, Inc. PRME.O:
PRIME MEDICINE ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PM647 IN ALPHA-1 ANTITRYPSIN DEFICIENCY
PRIME MEDICINE, - INITIAL CLINICAL DATA FOR PM647 EXPECTED IN 2027
Source text: ID:nGNX5xYwfb
Further company coverage: PRME.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease